You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Russia plans to begin trial of Sputnik V Covid-19 vaccine in India in Sept

Dmitriev told Sputnik that the clinical trials in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil will begin this month

Coronavirus Vaccine | clinical trials | Russia


coronavirus, coronavirus vaccine
According to Russian researchers, Sputnik V is a human adenoviral vector vaccine which fights against coronavirus disease.

The of Sputnik V vaccine for will be held this month in several countries including India, confirmed Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) on Monday.

Dmitriev told Sputnik that the in Saudi Arabia, United Arab Emirates (UAE), the Philippines, and Brazil will begin this month.

"The post-registration studies involving more than 40,000 people started in on August 26, before AstraZeneca has started its Phase 3 trial in the US with 30,000 participants. in Saudi Arabia, United Arab Emirates (UAE), the Philippines, and Brazil will begin this month. The preliminary results of the Phase 3 trial will be published in October-November 2020," said Dmitriev.

was in close dialogue with the Indian government and the leading drug manufactures of regarding the localization of production of Sputnik V vaccine in India.

On August 11, the Sputnik V vaccine developed jointly by RDIF and the Gamaleya National Research Center of Epidemiology and Microbiology was registered by the Ministry of Health of and became the world's first registered vaccine against Covid-19.

According to Russian researchers, Sputnik V is a human adenoviral vector vaccine which fights against disease.

"India has historically been a very important partner of Russia. India is one of the leading countries in production. Around 60 percent of all the vaccines in the world are produced in India. We are in close dialogue with the corresponding ministries and the India government and the leading manufacturer of the country regarding localisation of production of Sputnik V vaccine in India. And we have achieved certain agreements with the leading companies," Dmitriev said earlier in response to an ANI query on the talks between India and the Russian government on Sputnik V vaccine.

"We do recognise India and it's potential to become one of the support for the production of the vaccine not only in Indian markets but for other countries too. We very much appreciate the well- balanced approach expressed by the Indian partners as from the very beginning they started asking questions how our vaccine works and we appreciate it that they did not try to attack our vaccine but try to understand it," Dmitriev adding that their (India's) desire to understand our vaccine got to realize that their approach based on the human adenoviral vaccine platform is the most reasonable approach.

On September 4, a medical journal The Lancet has published the results of clinical trials of Phase I-II of the Russian vaccine demonstrating its safety and efficacy."Phase I-II clinical trials of Sputnik V showed no serious adverse events (SAE, Grade 3) for any of the criteria, while the incidence of serious adverse events for other candidate vaccines ranged from 1 per cent to 25 per cent," RDIF press note stated.

"In 100 per cent of participants in the clinical trials, Sputnik V generated a stable humoral and cellular immune response. The level of virus-neutralizing antibodies of volunteers vaccinated with Sputnik V was 1.4-1.5 times higher than the level of antibodies of patients who had recovered from Covid-19," RDIF press note further read.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, September 07 2020. 22:34 IST